Northern Trust
MIRM icon

Northern Trust’s Mirum Pharmaceuticals MIRM Stock Holding History

Northern Trust’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.5M Buy
394,920
+20,056
+5% +$1.89M ﹤0.01% 1310
2025
Q4 		$29.6M Sell
374,864
-10,472
-3% -$752K ﹤0.01% 1419
2025
Q3 		$28.2M Sell
385,336
-17,060
-4% -$1.08M ﹤0.01% 1469
2025
Q2 		$20.5M Buy
402,396
+13,475
+3% +$600K ﹤0.01% 1632
2025
Q1 		$17.5M Sell
388,921
-10,623
-3% -$501K ﹤0.01% 1704
2024
Q4 		$16.5M Buy
399,544
+32,059
+9% +$1.34M ﹤0.01% 1819
2024
Q3 		$14.3M Buy
367,485
+90,119
+32% +$3.59M ﹤0.01% 1842
2024
Q2 		$9.48M Sell
277,366
-3,713
-1% -$97.3K ﹤0.01% 2030
2024
Q1 		$7.06M Sell
281,079
-6,956
-2% -$191K ﹤0.01% 2272
2023
Q4 		$8.5M Buy
288,035
+12,801
+5% +$387K ﹤0.01% 2172
2023
Q3 		$8.7M Buy
275,234
+1,375
+0.5% +$37.7K ﹤0.01% 2103
2023
Q2 		$7.08M Buy
273,859
+59,662
+28% +$1.59M ﹤0.01% 2293
2023
Q1 		$5.15M Buy
214,197
+1,512
+0.7% +$34.5K ﹤0.01% 2455
2022
Q4 		$4.15M Buy
212,685
+4,523
+2% +$89.4K ﹤0.01% 2599
2022
Q3 		$4.37M Buy
208,162
+31,396
+18% +$756K ﹤0.01% 2573
2022
Q2 		$3.44M Buy
176,766
+90,439
+105% +$2.13M ﹤0.01% 2749
2022
Q1 		$1.9M Sell
86,327
-2,908
-3% -$59.3K ﹤0.01% 3130
2021
Q4 		$1.42M Buy
89,235
+490
+0.6% +$7.62K ﹤0.01% 3399
2021
Q3 		$1.77M Sell
88,745
-7,233
-8% -$118K ﹤0.01% 3350
2021
Q2 		$1.66M Sell
95,978
-957
-1% -$17.1K ﹤0.01% 3405
2021
Q1 		$1.92M Sell
96,935
-1,399
-1% -$26.8K ﹤0.01% 3266
2020
Q4 		$1.72M Sell
98,334
-2,655
-3% -$52.2K ﹤0.01% 3268
2020
Q3 		$1.95M Buy
100,989
+635
+0.6% +$13.6K ﹤0.01% 3077
2020
Q2 		$1.95M Buy
100,354
+30,448
+44% +$509K ﹤0.01% 3055
2020
Q1 		$978K Buy
69,906
+23,294
+50% +$382K ﹤0.01% 3231
2019
Q4 		$1.14M Buy
46,612
+9,799
+27% +$104K ﹤0.01% 3354
2019
Q3 		$370K Buy
+36,813
New +$452K ﹤0.01% 3616

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Northern Trust's MIRM Position: Q1 2026 in Review

Northern Trust increased its Mirum Pharmaceuticals (MIRM) stake by 5.4% in Q1 2026, buying an estimated $1.89M and bringing the position to 394,920 shares worth $36.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1310.

Northern Trust first reported a position in MIRM in Q3 2019 and has held it in 27 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Northern Trust held 394,920 shares of Mirum Pharmaceuticals worth $36.5M as of Q1 2026.
  • Northern Trust bought 20,056 Mirum Pharmaceuticals shares in Q1 2026, an estimated $1.89M.
  • Mirum Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1310 holding.
  • Northern Trust first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 27 quarters since.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.